|
1
|
Lopez-Beltran A, Cookson MS, Guercio BJ
and Cheng L: Advances in diagnosis and treatment of bladder cancer.
BMJ. 384:e0767432024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dyrskjøt L, Hansel DE, Efstathiou JA,
Knowles MA, Galsky MD, Teoh J and Theodorescu D: Bladder cancer.
Nat Rev Dis Primers. 9:582023. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Abou Chakra M, Duquesne I, Mima M, Moussa
M and O'Donnell MA: Global insights into the management of
BCG-unresponsive non-muscle invasive bladder cancer: A narrative
review of provider surveys. Transl Androl Urol. 14:3782–3793. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Witjes JA, Bruins HM, Cathomas R, Compérat
EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A,
Neuzillet Y, et al: European association of urology guidelines on
muscle-invasive and metastatic bladder cancer: Summary of the 2020
guidelines. Eur Urol. 79:82–104. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lidagoster S, Ben-David R, De Leon B and
Sfakianos JP: BCG and alternative therapies to BCG therapy for
Non-Muscle-Invasive bladder cancer. Curr Oncol. 31:1063–1078. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Babjuk M, Burger M, Capoun O, Cohen D,
Compérat EM, Dominguez Escrig JL, Gontero P, Liedberg F,
Masson-Lecomte A, Mostafid AH, et al: European association of
urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1,
and Carcinoma in Situ). Eur Urol. 81:75–94. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
de Jong FC, Laajala TD, Hoedemaeker RF,
Jordan KR, van der Made ACJ, Boevé ER, van der Schoot DKE,
Nieuwkamer B, Janssen EAM, Mahmoudi T, et al: Non-muscle-invasive
bladder cancer molecular subtypes predict differential response to
intravesical Bacillus Calmette-Guérin. Sci Transl Med.
15:eabn41182023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Koch GE, Smelser WW and Chang SS: Side
effects of intravesical BCG and chemotherapy for bladder cancer:
What they are and how to manage them. Urology. 149:11–20. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pichler R, Stäblein J, Mari A, Afferi L,
D'Andrea D, Marcq G, Del Giudice F, Soria F, Caño-Velasco J,
Subiela JD, et al: Treating BCG-Induced cystitis with combined
chondroitin and hyaluronic acid instillations in bladder cancer. J
Clin Med. 13:20312024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mostafid AH, Palou Redorta J, Sylvester R
and Witjes JA: Therapeutic options in high-risk non-muscle-invasive
bladder cancer during the current worldwide shortage of bacille
Calmette-Guérin. Eur Urol. 67:359–360. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Katz A: Sanofi's halt of BCG production
worries bladder cancer patients and urologists. https://www.onclive.com/view/sanofis-halt-of-bcg-production-worries-bladder-cancer-patients-and-urologistsApril
22–2024
|
|
12
|
Kawada T, Yanagisawa T, Bekku K, Laukhtina
E, Deimling MV, Majdoub M, Chlosta M, Pradere B, Babjuk M, Gontero
P, et al: Low-dose or -number of BCG in non-muscle invasive bladder
cancer: Updated systematic review and meta-analysis. Immunotherapy.
15:933–943. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Choi SY, Ha MS, Kim JH, Chi BH, Kim JW,
Chang IH, Kim TH and Myung SC: Low-dose versus standard-dose
bacille Calmette-Guérin for non-muscle-invasive bladder cancer:
Systematic review and meta-analysis of randomized controlled
trials. Investig Clin Urol. 63:140–150. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kawada T, Yanagisawa T, Bekku K, Laukhtina
E, von Deimling M, Chlosta M, Pradere B, Teoh JY, Babjuk M, Araki M
and Shariat SF: The efficacy and safety outcomes of lower dose BCG
compared to intravesical chemotherapy in non-muscle-invasive
bladder cancer: A network meta-analysis. Urol Oncol. 41:261–273.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Page MJ, McKenzie JE, Bossuyt PM, Boutron
I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan
SE, et al: The PRISMA 2020 statement: An updated guideline for
reporting systematic reviews. BMJ. 372:n712021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shea BJ, Reeves BC, Wells G, Thuku M,
Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E and
Henry DA: AMSTAR 2: A critical appraisal tool for systematic
reviews that include randomised or non-randomised studies of
healthcare interventions, or both. BMJ. 358:j40082017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sterne JAC, Savović J, Page MJ, Elbers RG,
Blencowe NS, Boutron I, Cates CJ, Cheng HY, Corbett MS, Eldridge
SM, et al: RoB 2: A revised tool for assessing risk of bias in
randomised trials. BMJ. 366:l48982019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuritz SJ, Landis JR and Koch GG: A
general overview of Mantel-Haenszel methods: Applications and
recent developments. Annu Rev Public Health. 9:123–160. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kontopantelis E and Reeves D: Performance
of statistical methods for meta-analysis when true study effects
are non-normally distributed: A comparison between
DerSimonian-Laird and restricted maximum likelihood. Stat Methods
Med Res. 21:657–659. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Morales A, Nickel JC and Wilson JW:
Dose-response of bacillus Calmette-Guerin in the treatment of
superficial bladder cancer. J Urol. 147:1256–1258. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yalçinkaya F, Kamiş L, Ozteke O, Günlüsoy
B, Yigitbaşi O and Ünal S: Prospective randomized comparison of
intravesical BCG therapy with standard dose versus low doses in
superficial bladder cancer. Int Urol Nephrol. 30:41–44. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kumar A, Dubey D, Bansal P, Mandhani A and
Naik S: Urinary interleukin-8 predicts the response of standard and
low dose intravesical bacillus Calmette-Guerin (modified Danish
1331 strain) for superficial bladder cancer. J Urol. 168:2232–2235.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Martínez-Piñeiro JA, Flores N, Isorna S,
Solsona E, Sebastián JL, Pertusa C, Rioja LA, Martínez-Piñeiro L,
Vela R, Camacho JE, et al: Long-term follow-up of a randomized
prospective trial comparing a standard 81 mg dose of intravesical
bacille Calmette-Guérin with a reduced dose of 27 mg in superficial
bladder cancer. BJU Int. 89:671–680. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Irie A, Uchida T, Yamashita H, Matsumoto
K, Satoh T, Koh H, Shimura S, Iwamura M and Baba S: Sufficient
prophylactic efficacy with minor adverse effects by intravesical
instillation of low-dose bacillus CalmetteGuérin for superficial
bladder cancer recurrence. Int J Urol. 10:183–189. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Martínez-Piñeiro JA, Martínez-Piñeiro L,
Solsona E, Rodríguez RH, Gómez JM, Martín MG, Molina JR, Collado
AG, Flores N, Isorna S, et al: Has a 3-fold decreased dose of
bacillus Calmette-Guerin the same efficacy against recurrences and
progression of T1G3 and Tis bladder tumors than the standard dose?
Results of a prospective randomized trial. J Urol. 174:1242–1247.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Vijjan V, Mandhani A, Kapoor R, Dubey D,
Srivastava A, Ansari MS, Pratipal S and Anant K: A randomized trial
comparing low dose (40 or 80 mg) with standard dose (120 mg) of
bacillus Calmette-Guerin for superficial bladder cancer. Indian J
Urol. 22:317–321. 2006. View Article : Google Scholar
|
|
27
|
Liu J, Li S, Li S and Li J: Immunization
& Side Effect Comparison of BCG Intracavitary Perfusion at
Different Dose for Patients with Bladder Carcinoma After Surgery.
China Pharmacy. 360–361. 2007.(In Chinese).
|
|
28
|
Zhang H, Zhou C, Ma T, Wang S and Ge N:
Effect of low dose bacillus Calmette-Guerin intravesical
instillation against recurrence of superficial bladder cancer. J
Shandong Univ (Health Sciences). 46:513–519. 2008.(In Chinese).
|
|
29
|
Zheng G, Cao Z, Wang Y and Huang Y:
Comparison of the effect of intro vesical instillation of different
dose for superficial TCC. Xiandai Miniao Waike Zaxhi. 13:279–281.
2008.(In Chinese).
|
|
30
|
Gong H, Tan M, Liu Z, Shen B, Zhu J, Bao E
and Fan Y: Clinical observation of bladder perfusion with different
doses of BCG vaccine in treatment of superficial bladder cancer.
Modern Journal of Integrated Traditional Chinese and Western
Medicine. 18:1357–1358. 2009.(In Chinese).
|
|
31
|
Inamoto T, Ubai T, Nishida T, Fujisue Y,
Katsuoka Y and Azuma H: Comparable effect with minimal morbidity of
low-dose Tokyo 172 strain compared with regular dose Connaught
strain as an intravesical bacillus Calmette-Guérin prophylaxis in
nonmuscle invasive bladder cancer: Results of a randomized
prospective comparison. Urol Ann. 5:7–12. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yokomizo A, Kanimoto Y, Okamura T, Ozono
S, Koga H, Iwamura M, Tanaka H, Takahashi S, Tsushima T, Kanayama
HO, et al: Randomized controlled study of the efficacy, safety and
quality of life with low dose bacillus Calmette-guérin instillation
therapy for nonmuscle invasive bladder cancer. J Urol. 195:41–46.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gore JL, Wolff EM, Comstock BA, Follmer
KM, Nash MG, Basu A, Chisolm S, MacLean DB, Lee JR, Lotan Y, et al:
Protocol of the comparison of intravesical therapy and surgery as
treatment options (CISTO) study: A pragmatic, prospective
multicenter observational cohort study of recurrent high-grade
non-muscle invasive bladder cancer. BMC Cancer. 23:11272023.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gore JL, Wolff EM, Nash MG, Comstock BA,
Gilbert SM, Chang SS, Chisolm S, MacLean DB, Wright JL, Kates MR,
et al: Twelve-month results from the CISTO study comparing radical
cystectomy versus Bladder-sparing therapy for recurrent High-Grade
Non-Muscle-invasive bladder cancer. J Clin Oncol. 44:274–285. 2026.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Elmasri M, Clark A and Grundy L:
Peripheral mechanisms underlying bacillus Calmette-Guerin-Induced
lower urinary tract symptoms (LUTS). Brain Sci. 14:12032024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Bourlotos G, Baigent W, Hong M, Plagakis S
and Grundy L: BCG induced lower urinary tract symptoms during
treatment for NMIBC-Mechanisms and management strategies. Front
Neurosci. 17:13270532024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Carneiro BDB, Sanches BCF, Andrade DL,
Voris BRI and Reis LO: Moreau strain bacillus Calmette-guérin low
versus standard dose in the treatment of High-Grade T1 bladder
cancer: A retrospective observational cohort study. Clin Genitourin
Cancer. 17:e779–e783. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Quan Y, Jeong CW, Kwak C, Kim HH, Kim HS
and Ku JH: Dose, duration and strain of bacillus Calmette-Guerin in
the treatment of nonmuscle invasive bladder cancer: Meta-analysis
of randomized clinical trials. Medicine (Baltimore). 96:e83002017.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morales A, Eidinger D and Bruce AW:
Intracavitary Bacillus Calmette-Guerin in the treatment of
superficial bladder tumors. J Urol. 116:180–183. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lamm DL, Blumenstein BA, Crissman JD,
Montie JE, Gottesman JE, Lowe BA, Sarosdy MF, Bohl RD, Grossman HB,
Beck TM, et al: Maintenance bacillus CalmetteGuerin immunotherapy
for recurrent TA, T1 and carcinoma in situ transitional cell
carcinoma of the bladder: A randomized Southwest Oncology Group
Study. J Urol. 163:1124–1129. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Wang YH, Cao YW, Yang XC, Niu HT, Sun LJ,
Wang XS and Liu J: Effect of TLR4 and B7-H1 on immune escape of
urothelial bladder cancer and its clinical significance. Asian Pac
J Cancer Prev. 15:1321–1326. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lu Y, Huang X, Liu X, He Y, Hu Z, Xu W,
Cao G and He W: Remodels the immunosuppressive tumor
microenvironment by combination of bacillus Calmette-Guérin and
anti-PD-L1 in an orthotopic triple-negative breast cancer mouse
model. Onco Targets Ther. 14:2247–2258. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yoon HY, Chang IH, Goo YT, Kim CH, Kang
TH, Kim SY, Lee SJ, Song SH, Whang YM and Choi YW: Intravesical
delivery of rapamycin via folate-modified liposomes dispersed in
thermo-reversible hydrogel. Int J Nano medicine. 14:6249–6268.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Cho MJ, Kim MJ, Kim K, Choi YW, Lee SJ,
Whang YM and Chang IH: The immunotherapeutic effects of recombinant
Bacillus Calmette-Guérin resistant to antimicrobial peptides on
bladder cancer cells. Biochem Biophys Res Commun. 509:167742019.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Whang YM, Yoon DH, Hwang GY, Yoon H, Park
SI, Choi YW and Chang IH: Liposome-encapsulated bacillus
Calmette-Guérin cell wall skeleton enhances antitumor efficiency
for bladder cancer in vitro and in vivo via induction of
AMP-activated protein kinase. Cancers (Basel). 12:36792020.
View Article : Google Scholar : PubMed/NCBI
|
